Hosted by Unknown Host · 🇺🇸 US · EN · 100 episodes
Established thought leaders with verified media credentials.
The ASCO Daily News Podcast features oncologists discussing the latest research and therapies in their areas of expertise.
Unknown Host hosts ASCO Daily News, a health show with 100 episodes published.
Dr. Megan Kruse and Dr. Hope Rugo discuss practice-changing data in metastatic breast cancer and critical shifts in the treatment of early-stage disease that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL T
Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT
Dr. Pauline Funchain and Dr. Allison Betof discuss practice-changing and paradigm-shifting abstracts in melanoma, Merkel cell carcinoma, and cellular therapies that were presented at the 2026 ASCO Annual Meeting. LINK TO
Dr. Nilo Azad and Dr. Aparna Parikh discuss high-impact studies in gastrointestinal cancers and other novel treatment approaches that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT
Dr. Marc Braunstein and Dr. Adam Kittai highlight top research on hematologic malignancies from the 2026 ASCO Annual Meeting, including studies on lymphoid malignancies, multiple myeloma, and plasma cell disorders. LINK
Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIP
Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial i
Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Mer
Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immun
Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapi
In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option
Dr. Monty Pal and Dr. Jo Chien preview new research, hot topics, and emerging innovations in oncology that will be presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT
Google DeepMind's Dr. Alan Karthikesalingam and Google research scientist Anil Palepu sit down with Dr. Monty Pal to discuss the potential of Articulate Medical Intelligence Explorer (AMIE), a large language model-based
Dr. Monty Pal and Dr. Arturo Loaiza-Bonilla discuss the institutional risks in the use of artificial intelligence (AI) in clinical practice and how overreliance on AI could erode essential skills. They also highlight pra
Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving
Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA
Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr
Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based
Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body o
Dr. Monty Pal and Dr. Mary Feng discuss the latest advances in metastatic colorectal, gastric, and gastroesophageal cancers that were presented at the 2026 ASCO Gastrointestinal Cancers Symposium.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
ASCO Daily News has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
ASCO Daily News is hosted by Unknown Host. The show is categorised under health (fitness) and has published 100 episodes.
ASCO Daily News has published 100 episodes.
ASCO Daily News regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
ASCO Daily News is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
ASCO Daily News hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of ASCO Daily News average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates ASCO Daily News's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 11 days ago.
